Eli Lilly says weight-loss pill a candidate for speedy approval under new US program
Update: 2025-10-31
Description
Eli Lilly's experimental weight-loss pill, orforglipron, has qualified for a fast-tracked FDA review, potentially reaching the market in just one to two months. This pill, along with Lilly's existing treatments Zepbound and Mounjaro, has shown promising results in clinical trials, with patients losing over twelve percent of their body weight. The company's strong performance in the weight-loss drug market has boosted its revenue and market confidence, with analysts predicting the global market could reach $150 billion by 2030. Lilly has raised its financial forecasts, expecting to generate between $63 billion and $63.5 billion in revenue this year, with earnings between $23 and $23.70 per share.
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
